Follow The Filings

NMRA Neumora Therapeutics

Neumora Therapeutics earnings company data as of 3:01 PM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —
FY2026 Q2 14 Aug EPS — -0.23 —
Rev — — —

Insider trades

Open-market buys and sales by NMRA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NMRA insider trades
  • $15M bought by 3 insiders
  • $702K sold by 1 insider outside a trading plan
  • $307K sold by 1 insider under 10b5-1 plans
  1. Daljit Singh Aurora See Remarks
    Sale
    $270K 176,060 shares at $1.53
    Traded Aug 20–21 Filed Aug 21
    ↗
  2. Daljit Singh Aurora See Remarks
    Sale
    $432K 277,773 shares at $1.55
    Traded Aug 17–19 Filed Aug 19
    ↗
  3. Daljit Singh Aurora See Remarks
    Planned sale
    $307K 114,703 shares at $2.68 100% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗
  4. Kristina Burow Director
    Buy
    $5M 1,915,700 shares at $2.61 +46% to stake
    Traded Oct 27, 2025 Filed Oct 29, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 16 option exercises and 4 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 2.02,5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 1.01,2.03,2.05,7.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 3.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.